Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Ellis

Showing results (131-140 of 222) with videos related to

Pageof 23
Sort By:
Circulation|November 28, 2001
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme riseS G Ellis, S J Brener, A M Lincoff, et al.
Journal of the American College of Cardiology|November 20, 1998
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor BlockadeS G Ellis, A M Lincoff, D Miller, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Journal of the American College of Cardiology|February 1, 1989
Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable anginaJ M Nicklas, E J Topol, N Kander, et al.
Circulation|February 1, 1988
Angiographic and clinical predictors of acute closure after native vessel coronary angioplastyS G Ellis, G S Roubin, S B King, et al.
Journal of the American College of Cardiology|February 1, 1988
In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 proceduresS G Ellis, G S Roubin, S B King, et al.
Journal of the American College of Cardiology|May 1, 1989
Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarctionS G Ellis, W W O'Neill, E R Bates, et al.
American Heart Journal|April 1, 1991
Submaximal exercise thallium-201 SPECT for assessment of interventional therapy in patients with acute myocardial infarctionR E Stewart, N Kander, J E Juni, et al.
The American Journal of Cardiology|September 21, 2001
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive proteinD P Chew, D L Bhatt, M A Robbins, et al.
Journal of the American College of Cardiology|April 1, 1995
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) GroupS G Ellis, M J Cowley, P L Whitlow, et al.
Pageof 23

Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
Circulation|November 28, 2001
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme riseS G Ellis, S J Brener, A M Lincoff, et al.
Journal of the American College of Cardiology|November 20, 1998
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor BlockadeS G Ellis, A M Lincoff, D Miller, et al.
American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.
Journal of the American College of Cardiology|February 1, 1989
Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable anginaJ M Nicklas, E J Topol, N Kander, et al.
Circulation|February 1, 1988
Angiographic and clinical predictors of acute closure after native vessel coronary angioplastyS G Ellis, G S Roubin, S B King, et al.
Journal of the American College of Cardiology|February 1, 1988
In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 proceduresS G Ellis, G S Roubin, S B King, et al.
Journal of the American College of Cardiology|May 1, 1989
Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarctionS G Ellis, W W O'Neill, E R Bates, et al.
American Heart Journal|April 1, 1991
Submaximal exercise thallium-201 SPECT for assessment of interventional therapy in patients with acute myocardial infarctionR E Stewart, N Kander, J E Juni, et al.
The American Journal of Cardiology|September 21, 2001
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive proteinD P Chew, D L Bhatt, M A Robbins, et al.
Journal of the American College of Cardiology|April 1, 1995
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) GroupS G Ellis, M J Cowley, P L Whitlow, et al.
Pageof 23